Cargando…
85 Clinical Efficacy of Recombinant Human C1 Inhibitor in Patients with Acute Hereditary Angioedema Attacks
BACKGROUND: Recombinant human C1 Inhibitor (rhC1INH) has been approved in Europe for the treatment of acute hereditary angioedema attacks. The efficacy of rhC1INH was demonstrated in 2 randomized-controlled trials. Open-label extension studies, where patients could be treated for subsequent HAE atta...
Autores principales: | Reshef, Avner, Riedl, Marc, Moldovan, Dumitru, Lockey, Richard F., Montinaro, Vincenzo, Suez, Daniel, Relan, Anurag, Cicardi, Marco, Zuraw, Bruce |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization Journal
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513148/ http://dx.doi.org/10.1097/01.WOX.0000411830.69753.fb |
Ejemplares similares
-
84 Immuno-Safety of Recombinant Human C1 Inhibitor in Patients With Hereditary Angioedema: An Integrated Analysis
por: Hack, Erik, et al.
Publicado: (2012) -
455 Characterization of the Factors Triggering an Edematous Attack in Hereditary Angioedema
por: Zotter, Zsuzsanna, et al.
Publicado: (2012) -
454 Efficacy of Icatibant Versus Fresh Frozen Plasma for Attacks of Hereditary Angioedema: Analysis of Indivudual Symptoms by Attack Site
por: Lara, Alicia, et al.
Publicado: (2012) -
588 Delayed Diagnosis of Hereditary Angioedema. A Case Report
por: González-Díaz, Sandra, et al.
Publicado: (2012) -
457 Clinical Features and Outcome of 82 Patients with Hereditary Angioedema
por: D'Ottaviano, Fabricio Loffredo, et al.
Publicado: (2012)